APOA1 and atherosclerosis: In addition to providing insights into the mechanism by which anti-ApoA-I autoantibodies are elicited in subjects without autoimmune disease, this observation provides a rationale for the development of new ApoA-I mimetic peptides with potential use in both diagnosis and targeted therapy of atherosclerosis and CVD.